Cervical carcinoma in the European Union: An update on disease burden, screening program state of activation, and coverage as of March 2014

International Journal of Gynecological Cancer

Volumn 25, Issue 3, 2015, Pages 474-483

  Altobelli, Emma ^a,b   Lattanzi, Amedeo ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b AUSL 4   (Italy)

Author keywords

Cancer; Cervical cancer; EU28; Screening

Indexed keywords

BELGIUM; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; COLPOSCOPY; COST EFFECTIVENESS ANALYSIS; CROATIA; CYPRUS; CYTOLOGY; CZECH REPUBLIC; DENMARK; EMERGENCY HEALTH SERVICE; ESTONIA; EUROPEAN UNION; FEMALE; FINLAND; FRANCE; GERMANY; GREECE; HEALTH INSURANCE; HUMAN; HUNGARY; IRELAND; ITALY; LIQUID BASED CYTOLOGY; LITHUANIA; LUXEMBOURG; MALTA; NETHERLANDS; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PERSISTENT INFECTION; POLAND; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; ROMANIA; SLOVAKIA; SLOVENIA; SPAIN; STANDARD; SWEDEN; UNITED KINGDOM; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; EARLY DIAGNOSIS; EUROPE; INCIDENCE; INSURANCE; MASS SCREENING; MORTALITY; ORGANIZATION AND MANAGEMENT; STATISTICS AND NUMERICAL DATA; UTERINE CERVICAL NEOPLASMS; VULNERABLE POPULATION;

EARLY DETECTION OF CANCER; EUROPE; EUROPEAN UNION; FEMALE; HUMANS; INCIDENCE; INSURANCE COVERAGE; INSURANCE, HEALTH; MASS SCREENING; UTERINE CERVICAL NEOPLASMS; VULNERABLE POPULATIONS;

EID: 84924405149     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000374     Document Type: Review

References (72)

1. Kesic V, Poljak M, Rogovskaya S. Cervical cancer burden and prevention activities in Europe. Cancer Epidemiol Biomarkers Prev. 2012;21:1423-1433.
2. Arbyn M, Anttila A, Jordan J, et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition - summary document. Ann Oncol. 2010;21:448-458.
3. Anttila A, Ronco G, Clifford G, et al. Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer. 2004;91:935-941.
4. Arbyn M, Raifu AO, Weiderpass E, et al. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer. 2009;45:2640-2648.
5. Commission Communication "Solidarity in health: reducing health inequalities in the EU" (COM [2009] 567 final of 20.10.2009). Available at: http://ec.europa.eu/health/ph-determinants/socio-economics/documents/com2009-en.pdf. Accessed December 15, 2013.
6. Marmot M, Allen J, Bell R, et al. WHO European review of social determinants of health and the health divide. Lancet. 2012;380:1011-1029.
7. "Report on reducing health inequalities in the EU," Committee on the Environment, Public Health and Food Safety, 8.2.2012. Available at: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&reference=A7-2011-0032&language=EN#title1. Accessed December 15, 2013.
8. Regional Committee for Europe Sixty - Second Session Malta, 10-13 September 2012: European Action Plan for Strengthening Public Health Capacities and Services. Available at: http://www.euro.who.int/-data/assets/pdf-file/0005/171770/RC62wd12rev1-Eng.pdf. Accessed December 14, 2013.
9. Marmot M. Health inequalities in the EU - Final report of a consortium. European Commission Directorate-General for Health and Consumers. http://ec.europa.eu/health/social-determinants/docs/healthinequalitiesineu-2013-en.pdf. Published December 2013. doi:10.2772/34426.
10. Ronco G, Anttila A. Cervical cancer screening in Europe - changes over the last 9 years. Eur J Cancer. 2009;45:2629-2631.
11. Anttila A, von Karsa L, Aasmaa A, et al. Cervical cancer screening policies and coverage in Europe. Eur J Cancer. 2009;45:2649-2658.
12. Bastos J, Peleteiro B, Gouveia J, et al. The state of the art of cancer control in 30 European countries in 2008. Int J Cancer. 2010;126:2700-2715.
13. International Agency for Research on Cancer. IARC Handbooks of Cancer Prevention, Vol. 10: Cervix Cancer Screening. Lyon, France: IARC Press; 2005. http://www.iarc.fr/en/publications/pdfs-online/prev/handbook10/HANDBOOK10.pdf.
14. Arbyn M, Anttila A, Jordan J, et al., eds. European Guidelines for Quality Assurance in Cervical Cancer Screening. 2nd ed. Luxembourg: Office for Official Publications of the European Communities; 2008:1-291.
15. Rásky É, Regitnig P, Schenouda M, et al. Quality of screening with conventional Pap smear in Austria - a longitudinal evaluation. BMC Public Health. 2013;13:998.
16. de Jonge E, Cloes E, Op de Beeck L, et al. A quasi-randomized trial on the effectiveness of an invitation letter to improve participation in a setting of opportunistic screening for cervical cancer. Eur J Cancer Prev. 2008;17:238-242.
17. Kostova P, Zlatkov V. Effectiveness of cervical screening - expectation and reality [in Bulgarian]. Akush Ginekol (Sofiia). 2000;39:23-24.
18. Maver PJ, Seme K, Korá T, et al. Cervical cancer screening practices in central and eastern Europe in 2012. Acta Dermatovenerol Alp Pannonica Adriat. 2013;22:7-19.
19. Ilardi M, Shikova E, Aurora - A European Network on Cervical Cancer Surveillance and Control in the New Member States. Analysis of the local contexts. Edited 2012. Available at: http://www.aurora-project.eu/upload/deliverables/D3-traduzioni/D3-ENG.pdf. Accessed January 18, 2014.
20. Májek O, Danes J, Zavoral M, et al. Czech National Cancer Screening Programmes in 2010 [in Czech]. Klin Onkol. 2010;23:343-353.
21. Kivistik A, Lang K, Baili P, et al. Women's knowledge about cervical cancer risk factors, screening, and reasons for non-participation in cervical cancer screening programme in Estonia. BMC Womens Health. 2011;11:43.
22. Finnish Cancer Registry. Available at: http://www.cancer.fi/syoparekisteri/en/mass-screening-registry/cervical-cancer-screening/screening-programme/. Accessed January 19, 2014.
23. National Institute of Cervical Cancer France. Available at: http://www.e-cancer.fr/depistage/cancer-du-col-de-luterus. Accessed January 18, 2014.
24. Kovacs A, Dobrossy L, Budai A, et al. The state of the organized cervical screening program in Hungary in 2006 [in Hungarian]. Orv Hetil. 2007;148:535-540.
25. Ronco G, Giubilato P, Naldoni C, et al. Extension of organised cervical cancer screening programmes in Italy and their process indicators, 2010 activity. Epidemiol Prev. 2012;36:1-96.
26. PASSI Project, Diagnosi Precoce del Tumore del Collo dell'Utero. Available at: http://www.epicentro.iss.it/passi/pdf2013/Report%20Screening%20Cervice%20-%20RmA.pdf. Accessed January 22, 2014.
27. Anttila A, Ronco G. Working Group on the Registration and Monitoring of Cervical Cancer Screening Programmes in the European Union; within the European Network for Information on Cancer (EUNICE). Description of the national situation of cervical cancer screening in the member states of the European Union. Eur J Cancer. 2009;45:2685-2708.
28. Viberga I, Engele L, Baili P. EUROCHIP Working Group. Past, present and future of the cervical cancer screening in Latvia. Tumori. 2010;96:529-537.
29. EUROCHIP-2 Final Report, Annex 13, EUROCHIP-2 in Malta. Available at: http://www.tumori.net/eurochip/report-2.php.Accessed January 28, 2014.
30. Meijer CJ, Snijders PJF. Cervical cancer in 2013: screening comes of age and treatment progress continues. Nat Rev Clin Oncol. 2014;11:77-78.
31. Spaczyński M, Karowicz-Bilińska A, Nowak-Markwitz E, et al. Podsumowanierealizacjipopulacyjnegoprogramuprofilaktykiiw czesnegowykrywaniarakaszyjkimacicy w ramachna rodowegoprogramuzwalaczaniachoróbnowotworowychlata 2007-2010. (Summary of the Population Program of Prevention and Early Detection of Cervical Cancer in the National Cancer Program 2007-2010). Poznań: CentralnyOśrodekKoordynuja¸cy; 2010. Polish. The Polish Association for Cervical Cancer. Available at: http://koalicjarsm.pl/?pageId=5&15. Accessed February 21, 2014.
32. Real O, Silva D, Leitão MA, et al. Cervical cancer screening in the central region of Portugal. Eur J Cancer. 2000;36:2247-2249.
33. Apostol I, Baban A, Nicula F, et al. Cervical cancer assessment in Romania under EUROCHIP-2. Tumori. 2010;96:545-552.
34. Ondrusova M, Zubor P, Ondrus D. Time trends in cervical cancer epidemiology in the Slovak Republic: reflection on the non-implementation of screening with international comparisons. Neoplasma. 2012;59:121-128.
35. Slovenian Cancer Registry. Available at: www.slora.si. Accessed January 22, 2014.
36. Martín-López R, Hernández-Barrera V, De Andres AL, et al. Breast and cervical cancer screening in Spain and predictors of adherence. Eur J Cancer Prev. 2010;19:239-245.
37. Eaker S, Adami HO, Granath F, et al. A large population-based randomized controlled trial to increase attendance at screening for cervical cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:346-354.
38. Cancer Research UK. Available at: http://www.cancerresearchuk.org/. Accessed January 22, 2014.
39. Gök M, Heideman DA, van Kemenade FJ, et al. HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study. BMJ. 2010;340:c1040.
40. Baay MF, Verhoeven V, Lambrechts HA, et al. Feasibility of collecting self-sampled vaginal swabs by mail: quantity and quality of genomic DNA. Eur J Clin Microbiol Infect Dis. 2009;28:1285-1289.
41. Tamalet C, Richet H, Carcopino X, et al. Testing for human papillomavirus and measurement of viral load of HPV 16 and 18 in self-collected vaginal swabs of women who do not undergo cervical cytological screening in Southern France. J Med Virol. 2010;82:1431-1437.
42. Tamalet C, Le Retraite L, Leandri FX, et al. Vaginal self-sampling is an adequate means of screening HR-HPV types in women not participating in regular cervical cancer screening. Clin Microbiol Infect. 2013;19:E44-E50.
43. Hesselink AT, Heideman DA, Steenbergen RD, et al. Methylation marker analysis of self-sampled cervico-vaginal lavage specimens to triage high-risk HPV-positive women for colposcopy. Int J Cancer. 2014;135:880-886.
44. Gyllensten U, Sanner K, Gustavsson I, et al. Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer. Br J Cancer. 2011;105:694-697.
45. Gök M, van Kemenade FJ, Heideman DA, et al. Experience with high-risk human papillomavirus testing on vaginal brush-based self-samples of non-attendees of the cervical screening program. Int J Cancer. 2012;130:1128-1135.
46. Deleré Y, Schuster M, Vartazarowa E, et al. Cervicovaginal self-sampling is a reliable method for determination of prevalence of human papillomavirus genotypes in women aged 20 to 30 years. J Clin Microbiol. 2011;49:3519-3522.
47. Igidbashian S, Boveri S, Spolti N, et al. Self-collected human papillomavirus testing acceptability: comparison of two self-sampling modalities. J Womens Health (Larchmt). 2011;20:397-402.
48. Silva J, Ribeiro J, Sousa H, et al. Oncogenic HPV types infection in adolescents and university women from North Portugal: from self-sampling to cancer prevention. J Oncol. 2011;2011:953469.
49. Snijders PJ, Verhoef VM, Arbyn M, et al. HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer. 2013;132:2223-2236.
50. Virtanen A, Nieminen P, Luostarinen T, et al. Self-sample HPV tests as an intervention for nonattendees of cervical cancer screening in Finland: a randomized trial. Cancer Epidemiol Biomarkers Prev. 2011;20:1960-1969.
51. Virtanen A, Anttila A, Luostarinen T, et al. Self-sampling versus reminder letter: effects on cervical cancer screening attendance and coverage in Finland. Int J Cancer. 2011;128:2681-2687.
52. Sancho-Garnier H, Tamalet C, Halfon P, et al. HPV self-sampling or the Pap-smear: a randomized study among cervical screening nonattenders from lower socioeconomic groups in France. Int J Cancer. 2013;133:2681-2687.
53. Piana L, Leandri FX, Le Retraite L, et al. L'auto-prélèvement vaginal à domicile pour recherche de papilloma virus à haut risque. Campagneexpérimentale du département des Bouches-du-Rhône [in French]. Bull Cancer. 2011;98:723-731.
54. Broberg G, Gyrd-Hansen D, Miao Jonasson J, et al. Increasing participation in cervical cancer screening: offering a HPV self-test to long-term non-attendees as part of RACOMIP, a Swedish randomized controlled trial. Int J Cancer. 2014;134:2223-2230.
55. Lindell M, Sanner K, Wikström I, et al. Self-sampling of vaginal fluid and high-risk human papillomavirus testing in women aged 50 years or older not attending Papanicolaou smear screening. BJOG. 2012;119:245-248.
56. Darlin L, Borgfeldt C, Forslund O, et al. Vaginal self-sampling without preservative for human papillomavirus testing shows good sensitivity. J Clin Virol. 2013;56:52-56.
57. Gök M, Heideman DA, van Kemenade FJ, et al. Offering self-sampling for human papillomavirus testing to non-attendees of the cervical screening programme: characteristics of the responders. Eur J Cancer. 2012;48:1799-1808.
58. Wikström I, Lindell M, Sanner K, et al. Self-sampling and HPV testing or ordinary Pap-smear in women not regularly attending screening: a randomised study. Br J Cancer. 2011;105:337-339.
59. Szarewski A, Cadman L, Mesher D, et al. HPV self-sampling as an alternative strategy in non-attenders for cervical screening - a randomised controlled trial. Br J Cancer. 2011;104:915-920.
60. Giorgi Rossi P, Marsili LM, Camilloni L, et al. The effect of self-sampled HPV testing on participation to cervical cancer screening in Italy: a randomised controlled trial (ISRCTN96071600). Br J Cancer. 2011;104:248-254.
61. Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383:524-532.
62. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13:78-88.
63. Altobelli E, Lattanzi A. Breast cancer in European Union: an update of screening programmes as of March 2014 (review). Int J Oncol. 2014;45:1785-1792.
64. Altobelli E, Lattanzi A, Paduano R, et al. Colorectal cancer prevention in Europe: burden of disease and status of screening programs. Prev Med. 2014;62:132-141.
65. Council of the European Union. Council Recommendation of 2 December 2003 on cancer screening (2003/878/EC). Off J Eur Union. 2003;L327:34-38.
66. European Commission. European Guidelines for Quality Assurance in Cervical Cancer Screening. 2nd ed. Luxembourg, Luxembourg: Office for Official Publications of the European Communities; 2008.
67. Arbyn M, Simoens C, Van Oyen H, et al. Analysis of 13 million individual patient records pertaining to Pap smears, colposcopies, biopsies and surgery on the uterine cervix (Belgium, 1996-2000). Prev Med. 2009;48:438-443.
68. Petry KU, Menton S, Menton M, et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer. 2003;88:1570-1577.
69. Comber H, Gavin A. Recent trends in cervical cancer mortality in Britain and Ireland: the case for population-based cervical cancer screening. Br J Cancer. 2004;91:1902-1904.
70. Llorca J, Rodriguez-Cundin P, Dierssen-Sotos T, et al. Cervical cancer mortality is increasing in Spanish women younger than 50. Cancer Lett. 2006;240:36-40.
71. Schmeink CE, Bekkers RL, Massuger LF, et al. The potential role of self-sampling for high-risk human papillomavirus detection in cervical cancer screening. Rev Med Virol. 2011;21:139-153.
72. Loos AH, Bray F, McCarron P, et al. Sheep and goats: separating cervix and corpus uteri from imprecisely coded uterine cancer deaths, for studies of geographical and temporal variations in mortality. Eur J Cancer. 2004;40:2794-2803.